Our Pipeline: Solid, And Set For Further Growth

Identifying and developing products that will improve the health and quality of life of patients remains a primary focus of Forest Laboratories. Our current product pipeline includes therapies in all stages of development and across a wide range of therapeutic areas, including cardiovascular disease, chronic obstructive pulmonary disease (COPD), mental health conditions, Alzheimer’s disease, infectious disease, and pain management. Below is a partial listing of our pipeline products.

Click here to see Aptalis pipeline products.

COMPOUND AREAS OF INTEREST PHASE I PHASE II PHASE III NDA
Cariprazine Schizophrenia/Bipolar Mania Complete response letter received
Nebivolol* + Valsartan Hypertension NDA filed
Memantine ER + Donepezil Alzheimer's Disease NDA filed
Aclidinium + Formoterol COPD Phase III completed; NDA being prepared  
Ceftazidime + Avibactam Infectious Disease Phase III  
 

Proof of Concept
Cariprazine MDD Adjunctive/Bipolar Depression Phase II    
Cebranopadol (GRT6005) Pain Management Phase II    
TRV027 Acute Heart Failure Phase II (with option to license post-Phase IIb)    
 

* Nebivolol is marketed in the U.S. as BYSTOLIC®
Memantine ER is marketed in the U.S. as NAMENDA XR®
Aclidinium is marketed in the U.S. as TUDORZA®

Except for the historical information contained herein, this site contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to update forward-looking statements contained here to reflect new information or future events or developments.